Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
H Holte, S Leppä, M Björkholm, O Fluge, S Jyrkkiö, J Delabie, C Sundström, M-L Karjalainen-Lindsberg, M Erlanson, A Kolstad, A Fosså, B Ostenstad, E Löfvenberg, M Nordström, R Janes, L M Pedersen, H Anderson, M Jerkeman, M Eriksson, H Holte, S Leppä, M Björkholm, O Fluge, S Jyrkkiö, J Delabie, C Sundström, M-L Karjalainen-Lindsberg, M Erlanson, A Kolstad, A Fosså, B Ostenstad, E Löfvenberg, M Nordström, R Janes, L M Pedersen, H Anderson, M Jerkeman, M Eriksson
Abstract
Background: Many patients with aggressive B-cell lymphomas and high clinical risk score still die of lymphoma after conventional R-CHOP chemoimmunotherapy. We hypothesized that intensified chemoimmunotherapy including systemic central nervous system (CNS) prophylaxis improves outcome and reduces the incidence of CNS-related events.
Patients and methods: Inclusion criteria were age 18-65 years, primary diffuse large B-cell lymphoma or grade III follicular lymphoma without clinical signs of CNS disease and negative cerebrospinal fluid cytology, age-adjusted International Prognostic Index 2-3 and WHO performance score 0-3. Treatment consisted of six courses of R-CHOEP-14 followed by a course of high-dose cytarabine and a course of high-dose methotrexate. Primary end point was failure-free survival (FFS) at 3 years.
Results: A total of 156 eligible patients with a median age of 54 years (range 20-64) were included. Three toxic deaths were observed. Three-year overall survival (OS) and FFS rates (median observation time 52 months for survivors) were 81% and 65%, respectively. Seven patients experienced CNS relapse, all within 6 months.
Conclusions: The results are promising with favorable 3-year OS and FFS rates, a low toxic death rate and a lower than expected number of CNS events. CNS progression might be further reduced by earlier CNS prophylaxis. CinicalTrials.gov. identifier NCT01502982.
Source: PubMed